Armata Pharmaceuticals (ARMP) Non-Current Deferred Tax Liability (2016 - 2026)

Armata Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 14 years, most recently at $3.1 million for Q1 2026.

• Non-Current Deferred Tax Liability reached $3.1 million in Q1 2026 per ARMP's latest filing, roughly flat from $3.1 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $3.1 million in Q1 2022 and bottomed at $3.1 million in Q1 2022.
• Median Non-Current Deferred Tax Liability over the past 5 years was $3.1 million (2022), compared with a mean of $3.1 million.
• Peak annual rise in Non-Current Deferred Tax Liability hit 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Over 5 years, Non-Current Deferred Tax Liability stood at $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024, then changed by 0.0% to $3.1 million in 2025, then changed by 0.0% to $3.1 million in 2026.
• Business Quant data shows Non-Current Deferred Tax Liability for ARMP at $3.1 million in Q1 2026, $3.1 million in Q4 2025, and $3.1 million in Q3 2025.

Peer Comparison